Welcome to our dedicated page for Moderna SEC filings (Ticker: MRNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moderna, Inc. filings document the regulatory, financial and governance record of a commercial-stage mRNA biotechnology company. Form 8-K reports cover operating results, Regulation FD updates, FDA communications for investigational vaccine submissions, material agreements, patent-litigation settlements and financing arrangements tied to the company's vaccine and therapeutic portfolio.
Proxy and annual-meeting filings disclose board elections, shareholder voting results, executive compensation and governance provisions, including bylaw amendments. The filings also record capital-structure matters such as credit facilities, risk and disclosure controls around pipeline development, and formal updates related to products including Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX.
Moderna, Inc. Chief Executive Officer Stephane Bancel reported receiving a grant of 250,932 stock options with an exercise price of $0.00 per share. According to the filing, 25% of this option will vest and become exercisable on March 1, 2027, with the remaining 75% vesting in twelve equal quarterly installments thereafter.
After this grant, Bancel is shown as directly holding 6,187,791 shares of Moderna common stock. The filing also reports additional common stock held indirectly through entities Boston Biotech Ventures and OCHA LLC in amounts of 9,210,686 and 6,564,880 shares, respectively, with Bancel disclaiming beneficial ownership except to the extent of any pecuniary interest.
Moderna, Inc. reported multiple equity transactions involving President Stephen Hoge. On March 1, 2026, he received a stock option covering 125,466 shares and a new award of 165,230 restricted stock units, each at an exercise or acquisition price of $0.00 per share. The new option and RSU awards begin vesting on March 1, 2027, with 25% vesting then and the remainder in twelve equal quarterly installments.
On February 27, 2026, several existing restricted stock unit awards were exercised, converting into common stock on a one-for-one basis. In connection with these vests, portions of the resulting shares were delivered at $51.71 per share to satisfy tax withholding obligations. Following these transactions, Hoge held 1,477,997 shares of common stock directly, plus additional indirect holdings of common stock by Valhalla, LLC and by a trust for his spouse and children, for which he disclaims beneficial ownership except for any pecuniary interest.
Moderna, Inc. Chief Legal Officer Shannon Thyme Klinger reported multiple equity transactions. She exercised stock options and restricted stock units that converted into common shares, then sold 13,885 common shares at $52.29 per share under a Rule 10b5-1 trading plan. Several grants of stock options and restricted stock units were also reported, and her direct common stock holdings were 59,689 shares after these transactions.
Moderna, Inc. Chief Financial Officer James M. Mock reported several equity compensation transactions. On March 1, 2026, he received a grant of 37,639 stock options and 49,569 restricted stock units (RSUs), with options and RSUs vesting 25% on March 1, 2027 and the remainder in twelve quarterly installments.
On February 27, 2026, multiple RSU awards converted into common stock on a one-for-one basis, and shares totaling 160, 375, and 4,788 were disposed of at $51.71 per share to cover tax withholding obligations. Following these transactions, Mock continued to hold common stock and derivative awards directly.
Moderna, Inc. president Stephen Hoge reported option exercises and a stock sale. On February 23, 2026, he exercised stock options covering 111,679 and 48,330 shares at an exercise price of $19.15 per share, receiving the same number of common shares. On the same date, he sold 160,009 Moderna common shares at an average price of $48.84 per share in an open-market transaction effected under a Rule 10b5‑1 trading plan adopted on November 13, 2025. After these transactions, he directly held 1,457,427 Moderna common shares. Separate indirect holdings include 4,116 shares held by Valhalla, LLC and 151,933 shares held by a trust for the benefit of his spouse and children, for which he disclaims beneficial ownership except to any pecuniary interest.
Moderna reports on its mRNA-focused business, highlighting three commercial vaccines—Spikevax and mNEXSPIKE for COVID-19 and mRESVIA for RSV—and 2025 revenue of $1.9 billion, largely from COVID vaccines. The company emphasizes a broad pipeline across infectious disease, oncology and rare diseases, including 35 therapeutic and vaccine programs, six in late-stage development.
Key programs include the flu vaccine mRNA-1010 and flu+COVID combo mRNA-1083 under regulatory review, a norovirus candidate mRNA-1403 in a large Phase 3 trial, and rare disease therapies for propionic acidemia and methylmalonic acidemia in registrational paths. In oncology, individualized therapy intismeran autogene (mRNA-4157), partnered with Merck, has shown sustained recurrence-free survival benefit in high-risk melanoma and expanded into multiple Phase 2 and 3 trials.
Moderna details a global manufacturing network in the U.S., UK, Canada and Australia, purpose-built facilities for personalized cancer vaccines, and heavy investment in platform, AI and digital tools to speed design, development and production. The filing also outlines extensive business risks, including regulatory uncertainty, competition, manufacturing complexity, cybersecurity and continued net losses in 2024 and 2025.
Moderna’s Chief Financial Officer, James M. Mock, reported equity compensation activity involving company common stock. On February 11, 2026, he acquired 2,630 shares at $0 through the vesting of performance-based restricted stock units granted on February 28, 2023.
On the same date, 1,278 shares were disposed of at $41.99 to satisfy tax withholding obligations linked to this vesting. After these transactions, Mock directly owned 45,224 shares of Moderna common stock.
Klinger Shannon Thyme reported multiple insider transaction types in a Form 4 filing for MRNA. The filing lists transactions totaling 3,964 shares at a weighted average price of $41.99 per share. Following the reported transactions, holdings were 55,861 shares.